(OPCH) Option Care Health - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 3.287m USD | Total Return: -33.5% in 12m
Avg Turnover: 109M
EPS Trend: 61.3%
Qual. Beats: 0
Rev. Trend: 99.3%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Option Care Health Inc (OPCH) provides home and alternate site infusion services across the United States. The company specializes in administering complex therapies for chronic and acute conditions, including immunoglobulin treatments, nutritional support, and therapies for inflammatory, neurological, and bleeding disorders. Its business model relies on a referral network of physicians, hospitals, and managed care organizations to transition patients from high-cost inpatient settings to lower-cost home environments.
The home infusion sector benefits from a shift toward value-based care, as home-based administration typically reduces overhead costs compared to traditional hospital stays. Because many of these therapies treat lifelong chronic conditions, the company maintains a recurring revenue profile driven by long-term patient clinical management. Investors may find it useful to examine ValueRay for deeper insights into the companys valuation metrics.
Headquartered in Bannockburn, Illinois, the company also provides specialized nursing services and high-risk pregnancy support. By managing the logistics of pharmaceutical distribution and clinical monitoring, Option Care Health functions as a critical intermediary between drug manufacturers and patients requiring long-term parenteral or enteral care.
- Expansion of chronic inflammatory and specialty infusion therapies drives high-margin revenue growth
- Strategic expansion of ambulatory infusion suites improves operational efficiency and margins
- Payer reimbursement rate fluctuations impact net revenue and service profitability
- Labor costs for specialized nursing staff influence overall operating expense ratios
- Growing demand for home-based clinical services supports long-term patient referral volume
| Net Income: 206.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -3.49 > 1.0 |
| NWC/Revenue: 8.21% < 20% (prev 7.44%; Δ 0.77% < -1%) |
| CFO/TA 0.08 > 3% & CFO 253.6m > Net Income 206.2m |
| Net Debt (-67.0m) to EBITDA (405.8m): -0.17 < 3 |
| Current Ratio: 1.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (158.2m) vs 12m ago -5.15% < -2% |
| Gross Margin: 18.00% > 18% (prev 0.20%; Δ 1.78k% > 0.5%) |
| Asset Turnover: 169.5% > 50% (prev 156.7%; Δ 12.74% > 0%) |
| Interest Coverage Ratio: 5.50 > 6 (EBITDA TTM 405.8m / Interest Expense TTM 61.1m) |
| A: 0.14 (Total Current Assets 1.20b - Total Current Liabilities 729.7m) / Total Assets 3.38b |
| B: 0.27 (Retained Earnings 922.3m / Total Assets 3.38b) |
| C: 0.10 (EBIT TTM 335.9m / Avg Total Assets 3.34b) |
| D: 0.45 (Book Value of Equity 922.3m / Total Liabilities 2.03b) |
| Altman-Z'' = 2.94 = A |
| DSRI: 0.99 (Receivables 516.4m/476.6m, Revenue 5.67b/5.19b) |
| GMI: 1.09 (GM 18.00% / 19.71%) |
| AQI: 1.01 (AQ_t 0.61 / AQ_t-1 0.60) |
| SGI: 1.09 (Revenue 5.67b / 5.19b) |
| TATA: -0.01 (NI 206.2m - CFO 253.6m) / TA 3.38b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 21.35 with a total of 2,312,796 shares traded.
Over the past week, the price has changed by +8.43%,
over one month by -23.56%,
over three months by -33.05% and
over the past year by -33.53%.
Option Care Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy OPCH.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 29.2 | 36.7% |
P/E Trailing = 16.3516
P/E Forward = 11.7647
P/S = 0.5799
P/B = 2.4337
P/EG = 1.1764
Revenue TTM = 5.67b USD
EBIT TTM = 335.9m USD
EBITDA TTM = 405.8m USD
Long Term Debt = 1.15b USD (from longTermDebt, last quarter)
Short Term Debt = 6.78m USD (from shortLongTermDebt, last quarter)
Debt = 110.4m USD (Leases only: 110.4m)
Net Debt = -67.0m USD (calculated: Debt 110.4m - CCE 177.3m)
Enterprise Value = 3.22b USD (3.29b + Debt 110.4m - CCE 177.3m)
Interest Coverage Ratio = 5.50 (Ebit TTM 335.9m / Interest Expense TTM 61.1m)
EV/FCF = 13.68x (Enterprise Value 3.22b / FCF TTM 235.4m)
FCF Yield = 7.31% (FCF TTM 235.4m / Enterprise Value 3.22b)
FCF Margin = 4.15% (FCF TTM 235.4m / Revenue TTM 5.67b)
Net Margin = 3.64% (Net Income TTM 206.2m / Revenue TTM 5.67b)
Gross Margin = 18.00% ((Revenue TTM 5.67b - Cost of Revenue TTM 4.65b) / Revenue TTM)
Gross Margin QoQ = 18.30% (prev 17.99%)
Tobins Q-Ratio = 0.95 (Enterprise Value 3.22b / Total Assets 3.38b)
Interest Expense / Debt = 55.35% (Interest Expense 61.1m / Debt 110.4m)
Taxrate = 25.67% (15.7m / 61.0m)
NOPAT = 249.7m (EBIT 335.9m * (1 - 25.67%))
Current Ratio = 1.64 (Total Current Assets 1.20b / Total Current Liabilities 729.7m)
Debt / Equity = 0.08 (Debt 110.4m / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = -0.17 (Net Debt -67.0m / EBITDA 405.8m)
Debt / FCF = -0.28 (Net Debt -67.0m / FCF TTM 235.4m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.17% (Net Income 206.2m / Total Assets 3.38b)
RoE = 15.28% (Net Income TTM 206.2m / Total Stockholder Equity 1.35b)
RoCE = 13.42% (EBIT 335.9m / Capital Employed (Equity 1.35b + L.T.Debt 1.15b))
RoIC = 9.47% (NOPAT 249.7m / Invested Capital 2.64b)
WACC = 6.42% (E(3.29b)/V(3.40b) * Re(6.64%) + (debt cost/tax rate unavailable))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.39 | Cagr: -5.63%
[DCF] Terminal Value 73.10% ; FCFF base≈279.6m ; Y1≈245.2m ; Y5≈198.1m
[DCF] Fair Price = 20.67 (EV 3.18b - Net Debt -67.0m = Equity 3.25b / Shares 157.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 61.28 | EPS CAGR: 9.50% | SUE: -0.40 | # QB: 0
Revenue Correlation: 99.31 | Revenue CAGR: 13.83% | SUE: -1.85 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.48 | Chg30d=+4.38% | Revisions=-57% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.53 | Chg30d=+8.23% | Revisions=-50% | Analysts=10
EPS current Year (2026-12-31): EPS=1.94 | Chg30d=+4.17% | Revisions=-54% | GrowthEPS=+12.9% | GrowthRev=+1.1%
EPS next Year (2027-12-31): EPS=2.05 | Chg30d=-3.41% | Revisions=-57% | GrowthEPS=+5.8% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: -57%